Program
Anti-CTLA-4 Monoclonal Antibody IBI310
Also written as “IBI310”, “IBI310&Sintilimab” and “IBI310 (anti-CTLA-4 antibody)”.
Its studies are mostly in Carcinoma, Hepatocellular · Colorectal Neoplasms · Uterine Cervical Neoplasms · Biliary Tract Neoplasms · Melanoma, led by Innovent Biologics.
Drug pageAnti-CTLA-4 Monoclonal Antibody IBI310: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 112 open or running | phase 3since Feb 18, 2020 | May 10, 2018 | Dec 31, 2027phase 3 · NCT07490262 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 10, 2018First study: phase 1 study in Advanced Solid TumorsFirst studyNCT03545971 · 53 enrolled · China
- Feb 4, 2020Phase 2 study in Colorectal NeoplasmsNCT04258111 · 4 enrolled · China
- Feb 18, 2020Phase 3 study in Acral Melanoma That Has Been Removed by SurgeryNCT04277663 · 136 enrolled · China
- Oct 12, 2020Phase 2 study in Advanced Cervical CancerNCT04590599 · 205 enrolled · China
- Jan 13, 2021Phase 3 study in Carcinoma, HepatocellularNCT04720716 · 344 enrolled · China
- Apr 23, 2021Phase 1 study in Healthy SubjectsNCT04868760 · 148 enrolled · China
- Jun 7, 2021Phase 1 study in NPCNCT04945421 · 30 enrolled · China
- Nov 1, 2021Phase 1 study in Carcinoma, Non-Small-Cell LungNCT05118334 · 30 enrolled · China
- Dec 6, 2022Phase 2 study in Advanced Biliary Tract CancerNCT05653180 · 20 enrolled · China
- May 26, 2023Phase 3 study in MSI-HNCT05890742 · 453 enrolled · China
- Mar 16, 2026Phase 3 study in Carcinoma, HepatocellularNCT07490262 · 680 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 3 study in Carcinoma, HepatocellularNCT07490262
- Apr 15, 2028Primary completion: phase 3 study in MSI-HNCT05890742
TargetBeta
“A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4;CTLA4), ”NCIt, by rule
Other programs on CTLA4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tremelimumabrule | AstraZeneca | phase 3 | 47 |
| cadonilimabrule | Akeso | phase 3 | 45 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| Anti-CTLA-4 Monoclonal Antibody SHR-8068rule | Jiangsu HengRui Medicine | phase 3 | 16 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| gotistobartrule | oncoc4-inc | phase 3 | 5 |
| zalifrelimabrule | Agenus | phase 2 | 6 |
| porustobartrule | harbour-biomed-guangzhou-co-ltd | phase 2 | 5 |
| lorigerlimabrule | MacroGenics | phase 2 | 4 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
| GB268rule | eddingpharm-zhuhai-co-ltd | phase 2 | 2 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07490262Carcinoma, Hepatocellular · China | 3 | Recruiting | Dec 31, 2027 | 680 |
| NCT05890742MSI-H · China | 3 | Active, not recruiting | Apr 15, 2028 | 453 |
| NCT05653180Advanced Biliary Tract Cancer · China | 2 | UNKNOWN | Dec 31, 2023 | 20 |
| NCT05118334Carcinoma, Non-Small-Cell Lung · China | 1 | Completed | Jul 31, 2022 | 30 |
| NCT04945421NPC · China | 1 | Completed | Apr 25, 2022 | 30 |
| NCT04868760Healthy Subjects · China | 1 | Completed | May 2, 2022 | 148 |
| NCT04720716Carcinoma, Hepatocellular · China | 3 | Completed | Dec 31, 2025 | 344 |
| NCT04590599Advanced Cervical Cancer · China | 2 | Completed | Nov 20, 2023 | 205 |
| NCT04277663Acral Melanoma That Has Been Removed by Surgery · China | 3 | Terminated | Feb 28, 2023 | 136 |
| NCT04258111Colorectal Neoplasms · China | 2 | Terminated | Oct 26, 2020 | 4 |
| NCT03545971Advanced Solid Tumors · China | 1 | Completed | Sep 10, 2021 | 53 |
How it is read
Names in the registry
- “IBI310”, 8 entries
- “IBI310&Sintilimab”, 1 entry
- “IBI310 (anti-CTLA-4 antibody)”, 1 entry
- “IBI310+IBI308”, 1 entry
Codes read as this program: IBI310.
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 2 studies
- Colorectal Neoplasms, 1 study
- Uterine Cervical Neoplasms, 1 study
- Biliary Tract Neoplasms, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.